360 A phase 1 study of an Off-the-Shelf, multi-neoantigen vector (ADXS-503) alone and in combination with pembrolizumab in subjects with metastatic non-small cell lung cancer (NSCLC)

• Suresh Ramalingam,
• Jonathan Goldman,
• Thomas Stinchcombe,
• Gregory Gerstner,
• Missak Haigentz,
• Surya Vangala,
• Megan Parsi,
• Victor Kabala,
• Dinesh Simkhada,
• Andres Gutierrez

Affiliations

Suresh Ramalingam

7Emory University, Atlanta, GA, USA

Jonathan Goldman

1University of California Los Angeles, CA, Los Angeles, CA, USA

Thomas Stinchcombe

2Duke University, Durham, NC, USA

Gregory Gerstner

3Illinois Cancer Care, Peoria, IL, USA

Missak Haigentz

4Morristown Medical Center, Morristown, NJ, USA

Surya Vangala

5Advaxis Inc, Princeton, NJ, USA

Megan Parsi

5Advaxis Inc, Princeton, NJ, USA

Victor Kabala

5Advaxis Inc, Princeton, NJ, USA

Dinesh Simkhada

5Advaxis Inc, Princeton, NJ, USA

Andres Gutierrez

6Advaxis.Inc, Princeton, NJ, USA